March 6 (Reuters) - Medicus Pharma Ltd MDCX.O:
MEDICUS PHARMA LTD ANNOUNCES POSITIVELY TRENDING INTERIM ANALYSIS FOR SKNJCT-003 PHASE 2 CLINICAL STUDY TO NON-INVASIVELY TREAT BASAL CELL CARCINOMA OF THE SKIN (BCC)
MEDICUS PHARMA LTD: D-MNA WAS WELL TOLERATED FOR BOTH DOSE LEVELS
MEDICUS PHARMA: PLANS TO SUBMIT ANALYSIS TO FDA UNDER PACKAGE SEEKING TYPE C MEETING WITH FDA IN Q2